<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857271</url>
  </required_header>
  <id_info>
    <org_study_id>2013-233</org_study_id>
    <secondary_id>NCI-2013-02219</secondary_id>
    <secondary_id>2013-233-004</secondary_id>
    <secondary_id>2013-233</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <nct_id>NCT01857271</nct_id>
  </id_info>
  <brief_title>Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
  <acronym>EVENT</acronym>
  <official_title>EValuation of Erlotinib as a Neoadjuvant Therapy in Stage III NSCLC Patients With EGFR Mutations (EVENT Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well erlotinib hydrochloride works before surgery in treating
      patients with stage III non-small cell lung cancer. Erlotinib hydrochloride may stop the
      growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving
      erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of
      normal tissue that needs to be removed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the rate of mediastinal nodal clearance and complete pathological response
      after neoadjuvant erlotinib (erlotinib hydrochloride) in patients with epidermal growth
      factor receptor (EGFR) mutated stage III non-small cell lung cancer (NSCLC).

      SECONDARY OBJECTIVES:

      I. To determine the progression free survival in patient population of EGFR mutated stage III
      NSCLC patients who are treated with neoadjuvant erlotinib therapy.

      II. To determine the overall survival. III. To estimate the overall response rate from
      neoadjuvant erlotinib. IV. To estimate the surgical resection rate. V. To evaluate the safety
      of neoadjuvant erlotinib.

      TERTIARY OBJECTIVES:

      I. To determine several molecular and cellular biomarkers in the tumors, the skin and the
      serum that are predictive of the efficacy of neoadjuvant erlotinib.

      OUTLINE:

      Patients receive erlotinib hydrochloride orally (PO) once daily (QD) for 2 months and then
      undergo thoracotomy.

      After completion of study treatment, patients are followed up at 30 days, every 3 months for
      1 year, and then every 6 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">August 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Mediastinal Nodal Clearance, Defined as Pathologically Negative N2 Disease in the Final Surgical Resection Specimen or Mediastinoscopy</measure>
    <time_frame>3 years 9 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Stage IIIA Non-Small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (erlotinib hydrochloride and thoracotomy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (erlotinib hydrochloride and thoracotomy)</arm_group_label>
    <other_name>Cp-358,774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo thoracotomy</description>
    <arm_group_label>Treatment (erlotinib hydrochloride and thoracotomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib hydrochloride and thoracotomy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven (either histologic or cytologic) diagnosis of stage IIIA or IIIB
             non-small cell lung cancer; (according to American Joint Committee on Cancer [AJCC]
             staging, 7th edition) within 4 weeks of registration; the patient should have
             histologically or cytologically confirmed N2 disease

          -  Activating mutation in EGFR

          -  No prior chemotherapy or radiation for lung cancer

          -  Patients may be potentially resectable or unresectable

          -  Stage III A or B disease, including no distant metastases- based on following
             diagnostic workup:

               -  History/physical examination prior to registration

               -  Computed tomography (CT) scan of the chest or positron emission tomography (PET)
                  scan within 28 days of study entry

               -  CT scan of abdomen or magnetic resonance imaging (MRI) of abdomen or PET scan
                  within 28 days of study entry

               -  An MRI of the brain or head CT scan with contrast within 28 days of study entry

               -  Total body PET scan within 28 days of study entry

               -  Mediastinoscopies are highly recommended

          -  Patients must have measurable or evaluable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Absolute neutrophil count (ANC) &gt;= 1,500 cells/ul

          -  Platelets &gt;= 100,000 cells/ul

          -  Hemoglobin &gt;= 9.0 g/dl (note: the use of transfusion or other intervention to achieve
             hemoglobin [Hgb] &gt;= g/dl is acceptable)

          -  Serum creatinine =&lt; 1.5 x upper limit of normal (ULN)

          -  Total bilirubin &lt; 2.0 times the institutional upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 2.5 x the ULN

          -  Women of childbearing potential must have:

               -  A negative serum or urine pregnancy test (sensitivity =&lt; 25 IU human chorionic
                  gonadotropin [HCG]/L) within 72 hours prior to the start of study drug
                  administration

               -  Persons of reproductive potential must agree to use and utilize an adequate
                  method of contraception throughout treatment and for at least 4 weeks after study
                  drug is stopped prior to study enrollment, women of childbearing potential must
                  be advised of the importance of avoiding pregnancy during trial participation and
                  the potential risk factors for an unintentional pregnancy

          -  Ability to take oral medication

          -  Patient must sign study specific informed consent prior to study entry

        Exclusion Criteria:

          -  Pleural or pericardial effusion

               -  Pleural effusions allowed if one of the following conditions are met: 1) negative
                  cytology after adequate sampling by thoracentesis 2) effusion seen on CT scan but
                  not on chest x-ray and deemed too small to tap under CT or ultrasound guidance

          -  Severe, active co-morbidity, defined as follows:

               -  Cardiac symptoms; any of the following should be considered for exclusion:

                    -  Uncontrolled angina, congestive heart failure or myocardial infarction (MI)
                       within (6 months)

                    -  Diagnosed congenital long QT syndrome

                    -  Any history of clinically significant ventricular arrhythmias (such as
                       ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)

                    -  Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (&gt; 450
                       msec)

          -  History of significant bleeding disorder unrelated to cancer, including:

               -  Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)

               -  Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor
                  VIII antibodies)

               -  Ongoing or recent (=&lt; 3 months) significant gastrointestinal bleeding

          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (e.g., infectious) illness

          -  Men and women who:

               -  Are unwilling or unable to use an acceptable method to avoid pregnancy for the
                  entire study period and for at least 4 weeks after cessation of study drug, or
                  women who:

                    -  Have a positive pregnancy test at baseline, or

                    -  Are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haiying Cheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <results_first_submitted>November 15, 2019</results_first_submitted>
  <results_first_submitted_qc>June 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2020</results_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Haiying Cheng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 5, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT01857271/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The patients were enrolled on 11/7/2013, 5/2014, and 9/24/2014.</recruitment_details>
      <pre_assignment_details>The study was difficult to enroll and eventually terminated/closed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Erlotinib Hydrochloride)</title>
          <description>Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo restaging procedures to evaluate for surgery.
Erlotinib Hydrochloride: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Erlotinib Hydrochloride and Thoracotomy)</title>
          <description>Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.
Erlotinib Hydrochloride: Given PO
Therapeutic Conventional Surgery: Undergo thoracotomy
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Two females, one male.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Mediastinal Nodal Clearance, Defined as Pathologically Negative N2 Disease in the Final Surgical Resection Specimen or Mediastinoscopy</title>
        <time_frame>3 years 9 months</time_frame>
        <population>The study was closely prematurely due to poor accrual. No final analysis was performed due to very low number of subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Erlotinib Hydrochloride and Thoracotomy)</title>
            <description>Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.
Erlotinib Hydrochloride: Given PO
Therapeutic Conventional Surgery: Undergo thoracotomy
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Mediastinal Nodal Clearance, Defined as Pathologically Negative N2 Disease in the Final Surgical Resection Specimen or Mediastinoscopy</title>
          <population>The study was closely prematurely due to poor accrual. No final analysis was performed due to very low number of subjects.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Erlotinib Hydrochloride and Thoracotomy)</title>
          <description>Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.
Erlotinib Hydrochloride: Given PO
Therapeutic Conventional Surgery: Undergo thoracotomy
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Haiying Cheng</name_or_title>
      <organization>Albert Einstein Cancer Center</organization>
      <phone>718-405-8404</phone>
      <email>hcheng@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

